Genmab A/S (GMAB) Q2 2024 Earnings Conference Call August 8, 2024 12:00 PM ET
Company Participants
Jan van de Winkel - Chief Executive Officer
Tahamtan Ahmadi - Chief Medical Officer
Anthony Mancini - Chief Operating Officer
Anthony Pagano - Chief Financial Officer
Judith Klimovsky - Chief Development Officer
Conference Call Participants
Emily Field - Barclays Bank PLC
Xian Deng - UBS
Jonathan Chang - LeeRink Partners
Asthika Goonewardene - Truist Securities
Peter Verdult - Citigroup
Yaron Werber - TD Securities
Matthew Phipps - William Blair
Michael Schmidt - Guggenheim Partners
Rajan Sharma - Goldman Sachs
Yifeng Liu - HSBC
Mattias Haggblom - Handelsbanken
Operator
Hello, and welcome to the Genmab First Half 2024 Financial Results Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects.
Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.
I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.
Jan van de Winkel
Hello, and welcome to Genmab's conference call to discuss the company's financial results for the period ending June 30, 2024. With me today to present these results is our CFO, Anthony Pagano, our Chief Operating Officer, Anthony Mancini and our Chief Medical Officer, Tahi Ahmadi. For the Q&A, we will be joined by our Chief Development Officer, Judith Klimovsky. As already said, we will be making forward-looking statements, so please keep that in mind as we go through this call. During today's presentation, we will reference products being developed under some of our strategic collaborations. This slide acknowledges those relationships.
We have had a very exciting second quarter. The acquisition of ProfoundBio, which was completed in May was an historic event for Genmab and one that will enhance our long-term growth profile. In just a moment, you will hear from Tahi on some of the exciting next steps that we have planned for Rina-S, and later Anthony Pagano will walk you through the financial impact of the acquisition.